Skip to main content
NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%
SB

Standard BioTools Inc. (LAB)

NASDAQ • Healthcare

$0.6
-$0 (-0.9%)
Market open

Last close at October 26, 2026 at 20:00 UTC

Open$0.62
Previous Close$0.6
Day Range$0.59 - $0.62
Avg. Volume (3M)852.3K
Market Cap$238.9M
52 Week Range
$0.59$1.72
Next EarningsIn 7 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$20.1M100%
Gross Profitminus cost of goods$10.5M52%

Fundamentals & Financials

Revenue (TTM)
$84.5M
Net Income (TTM)
-$87.3M
EPS (TTM)
-$0.23
ROA (TTM)
-13.93%
Current Ratio
9.1

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+300.0%Q1 2026$0.06
0.0%Q2 2026-$0.02
-449.0%Q3 2026-$0.07
Next

Nov 3

in 7 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -449.0%

Standard BioTools’ revenue missed consensus and declined year over year in the second fiscal quarter of 2026, reported August 5, 2026, with revenue of about $20.1 million down ~8% (from $21.8 million a year ago) and trailing the $20.8 million estimate (-3.4%). The company posted EPS of -$0.07 (versus -$0.04 a year ago) and a net loss of roughly $26.8 million, narrowing ~20% from a net loss of about $33.5 million a year earlier. Gross profit came in around $10.5 million, translating to a gross margin of roughly 52%, while operating results remained deeply negative with operating income of about -$25.4 million and an operating margin near -126%. Cash flow from operations was negative at roughly $10.3 million. For the next period, consensus calls for EPS of -$0.02 on revenue of $18.8 million.

Next report — what to expect

Standard BioTools Inc. (LAB) reports next on November 3, 2026. Wall Street is looking for EPS of -$0.02 on revenue of $18.8 million. For trailing context, revenue fell -7.6% year over year last quarter. The company has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Standard BioTools Inc.

Standard BioTools Inc. develops life-science tools for healthcare and research markets, selling on NASDAQ as LAB. The company operates in medical technologies used by clinical, diagnostic, and research customers, and generated $85.3 million of revenue in FY2025. Its portfolio spans instrumentation, consumables, services, and assays, including the Hyperion spatial biology platform.

Name
Standard BioTools Inc.
CEO
Michael Egholm
Website
www.standardbio.com
Industry
Healthcare
Year Founded
1999
Employees
387

Today's Snapshot

AI-generated

LAB is trading 2.6% above yesterday's close, while its sector was flat. So far today, LAB is within 4.7% of its 52-week low of 0.59. Earnings are due from LAB on 3 November.

Trading Volume

Below 10d avg (689.2K)

500.5K

vs S&P 500 Today

Outperforming Market

+1.92%

Updated: October 27, 2026 at 16:54 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
LAB’s technical picture is biased to the downside, with price below most moving averages including the 200-day and momentum and MACD showing weakness while trend strength remains subdued. RSI and CCI are low, ATR is relatively large as a percentage of the share price signaling elevated proportional volatility, and on-balance volume is deeply negative, indicating distribution pressure. ADX indicates a lack of a strong trend, so moves lack conviction despite the clear bearish bias from moving averages and volume. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$0.63 - $0.93
    Sell
  • RSI (14)39.00
    Neutral
  • Stochastic %K (14, 3, 3)12.21
    Buy
  • MACD Level (12, 26)-0.03
    Sell

Peers & Related Assets

CBLLCeriBell, Inc.
$27.03-0.4%
BVSBioventus Inc.
$14.72-1.6%
CGEMCullinan Therapeutics, Inc.
$14.54+1.2%
VREXVarex Imaging Corporation
$18.41-0.1%
CTKBCytek Biosciences, Inc.
$5.89+5.4%
KIDSOrthoPediatrics Corp.
$24.02-2.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.